Conor Killmurray | Authors


Tipifarnib Elicits Encouraging Responses in Patients With Recurrent or Metastatic HNSCC

April 27, 2021

Results from the phase 2 study of farnesyltransferase inhibitor tipifarnib showed significant responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma and demonstrated that variant alle frequency could be a potential biomarker in this patient population.

Preclinical Research Shows Potential for EZH1/2 Dual Inhibitor In Relapsed/Refractory MCL

April 19, 2021

A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.

Ceralasertib/Durvalumab Combination Stands Out in HUDSON Trial for Patients With NSCLC

April 17, 2021

For patients non–small cell lung cancer who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.